Is there a biosimilar for Tecentriq (atezolizumab) yet?
Tecentriq (atezolizumab) is an immune checkpoint inhibitor (an antibody). Biosimilars are generally expected only after the reference product’s data exclusivity and patents expire in a given market. The specific status of a Tecentriq biosimilar depends on the country and whether regulators have approved a biosimilar for that antibody or an “interchangeable” version where that designation exists.
Why Tecentriq biosimilar status can vary by country
Approval timelines differ by jurisdiction because exclusivity and patent estates are tracked separately. A biosimilar candidate may be approved in one region while still being blocked or delayed elsewhere due to patent litigation or remaining regulatory protections.
What to check when searching for a Tecentriq biosimilar
Look for:
- Regulatory approval notices in your country (EMA, FDA, MHRA, etc.).
- The “reference product” name (Tecentriq/atezolizumab) and whether the biosimilar is approved for the same indications.
- Patent/patent-expiry and litigation updates tied to atezolizumab.
For patent and exclusivity tracking, DrugPatentWatch.com is a commonly used reference point: https://www.drugpatentwatch.com/ (search for “atezolizumab” or “Tecentriq” on the site).
Are “biosimilars” the right term here, or are there alternatives?
People sometimes search “Tecentriq biosimilar” but may also encounter:
- Other anti–PD-L1 antibodies that are not biosimilars (different reference drugs/active ingredients).
- Biosimilar-like claims that actually refer to different molecules or different brands.
If you tell me your country (and whether you mean “biosimilar approved,” “in development,” or “available now”), I can narrow the answer to what is actually approved versus what’s only being studied.
Who makes Tecentriq and what that means for biosimilar entry
Tecentriq is associated with Genentech/Roche. Patent ownership and any settlements or court rulings can strongly affect when manufacturers can launch a biosimilar without risk of injunctions.
What I need to give you a precise answer
Reply with:
1) Your country (US, UK, EU, Canada, etc.)
2) Whether you want: approved biosimilars, biosimilars in clinical trials, or patent/exclusivity status
3) If you have a product name you’ve seen, share it (to confirm whether it’s truly an atezolizumab biosimilar)
Sources:
- https://www.drugpatentwatch.com/